• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    2/13/24 10:17:50 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VACC alert in real time by email
    SC 13G/A 1 d778639dsc13ga.htm BARINTHUS BIOTHERAPEUTICS PLC Barinthus Biotherapeutics Plc

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

    Barinthus Biotherapeutics Plc

     

     

    (Name of Issuer)

    ADR, each representing one ordinary share

     

     

    (Title of Class of Securities)

    91864C107

     

     

    (CUSIP Number)

    31st December 2023

     

     

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.: 91864C107

    1. Names of Reporting Persons:  

    M&G Investment Management Limited (MAGIM)

    No I.R.S. Identification Number

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐

      (b)  ☐

    3. SEC Use Only

    4. Citizenship or Place of Organization: United Kingdom, England 

    Number of Shares Beneficially Owned By Each Reporting Person With:

    5. Sole Voting Power: 5,197,349

    6. Shared Voting Power : 0

    7. Sole Dispositive Power: 5,197,349

    8. Shared Dispositive Power: 0

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 5,197,349

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

    11. Percent of Class Represented by Amount in Row (9): 13.48%

    12. Type of Reporting Person (See Instructions): IA

     

    2


    CUSIP No.: 91864C107

    1. Names of Reporting Persons:  

    Luxembourg Specialist Investment Fund FCP-RAIF

    No I.R.S. Identification Number

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐

      (b)  ☐

    3. SEC Use Only

    4. Citizenship or Place of Organization: United Kingdom, England 

    Number of Shares Beneficially Owned By Each Reporting Person With:

    5. Sole Voting Power: 0

    6. Shared Voting Power : 0

    7. Sole Dispositive Power: 0

    8. Shared Dispositive Power: 0

    9. Aggregate Amount Beneficially Owned by Each Reporting Person: 4,108,752

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

    11. Percent of Class Represented by Amount in Row (9): 10.65%

    12. Type of Reporting Person (See Instructions): IV

     

    3


    Item 1.

     

    (a)

    Name of Issuer: Barinthus Biotherapeutics Plc

     

    (b)

    Address of Issuer’s Principal Executive Offices: Unit 6-10, Zeus Building Rutherford Avenue, Harwell, Didcot, OX11 0DF, United Kingdom

    Item 2.

     

    (a)

    Name of Person Filing:

    M&G Investment Management Limited (MAGIM)

     

    (b)

    Address of Principal Business Office or, if none, Residence: 10 Fenchurch Avenue, London, EC3M 5AG, United Kingdom

     

    (c)

    Citizenship: United Kingdom, England

     

    (d)

    Title of Class of Securities: ADS, each representing one ordinary share

     

    (e)

    CUSIP Number: 91864C107

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ 

      Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b) ☐

      Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c) ☐

      Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d) ☐

      Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e) ☒

      An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f) ☐

      An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g) ☐

      A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

    (h) ☐

      A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) ☐

      A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) ☐

      A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

    (k) ☐

      Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    e) MAGIM is an investment adviser in accordance with s.240.13d-1(b)(1)(ii)(E)

    All the securities covered by this report are legally owned by MAGIMs Investment advisory clients, and none are directly owned by MAGIM. Luxembourg Specialist Investment Fund FCP-RAIF is a fonds commun de placement (FCP) reserved alternative investment fund incorporated in Luxembourg and authorized by the CSSF. It is not registered with the Securities Exchange Commission under the Investment Company Act of 1940

     

    4


    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    M&G Investment Management Limited

    (a) Amount beneficially owned: 5,197,349

    (b) Percent of class: 13.48%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 5,197,349

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 5,197,349

    (iv) Shared power to dispose or to direct the disposition of: 0

    Luxembourg Specialist Investment Fund FCP-RAIF

    (a) Amount beneficially owned: 4,108,752

    (b) Percent of class: 10.65%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  12 February 2024

     

    M&G Investment Management Limited
    By:  

     

        LOGO

     

    Name: Owen Smith
    Title: Position Reporting Manager

     

    Luxembourg Specialist Investment Fund FCP-RAIF

    By:  

     

        LOGO

     

    Name: Owen Smith
    Title: Position Reporting Manager

     

    6

    Get the next $VACC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VACC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VACC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pelletier Nadege

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:56:29 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Griffiths Graham

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:55:03 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Enright William

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    1/4/24 8:54:01 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    SEC Filings

    View All

    Vaccitech plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    1/5/24 4:15:12 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    12/22/23 4:01:12 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    11/9/23 4:32:00 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

    New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA. The company also announced today that it has changed its name to Barinthus Biotherapeu

    11/6/23 9:05:56 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

    OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows: KOL Webinar: Seeking a Functional Cure for Chronic Hepatis BWednesday, September 20, 2023 between 14:00-15:00 ET.To register for the event

    9/13/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

    8/10/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Financials

    Live finance-specific insights

    View All

    Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch

    8/10/23 8:00:00 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company's progress. "2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of o

    5/12/23 8:00:57 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

    OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company's progress. "2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment of three clinical trials, and initiate

    3/24/23 8:06:29 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VACC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)

    2/13/24 10:17:50 AM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vaccitech plc (Amendment)

    SC 13G/A - Vaccitech plc (0001828185) (Subject)

    1/20/23 1:35:01 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vaccitech plc

    SC 13G - Vaccitech plc (0001828185) (Subject)

    10/7/22 4:36:37 PM ET
    $VACC
    Biotechnology: Pharmaceutical Preparations
    Health Care